Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma

Translational data combines advanced artificial intelligence (AI), immunogenomics, histopathology, and spatial transcriptomics to provide mechanistic insights into therapeutic response and disease progression

Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.